OR WAIT 15 SECS
When the injector design is finalized, Stevanato Group will produce it at one of its manufacturing facilities using extensive tooling, molding, and assembly expertise.
Stevanato Group, an Italian-based glass primary packaging producer, announced it is entering into an exclusive licensing agreement with Haselmeier, a self-injection manufacturing and development company based in Switzerland and Germany, for the Axis-D pen-injector technology and intellectual property (IP) in the therapeutic area of diabetes care.
The new device will be an updated version of a European Medicnes Agency and FDA-approved pen-injector already on the market, according to an Oct. 7, 2019 press release. When the injector design is finalized, Stevanato Group will produce it at one of its manufacturing facilities using extensive tooling, molding, and assembly expertise.
“We are pleased and proud to have Stevanato Group as our strategic partner for Axis-D in [d]iabetes,” said Frédéric Gabriel, chief innovation officer at Haselmeier, in the press release. “Stevanato Group has demonstrated in past years a consistent development strategy coupled with unique integrated capabilities and is able to leverage Haselmeier’s pen injection platform to bring it to the next level. Such platform has already been proven in the market, from an IP, performance, and user perspective. It also demonstrates Haselmeier’s strategic orientation to exploit its IP over various paths, either with its own development and manufacturing capabilities or together with a strategic partner.”
“We value our relationship with Haselmeier as a device technology partner,” added Paolo Patri, chief technology officer at Stevanato Group, in the press release. “With this agreement, we continue to expand our portfolio of devices for patients suffering from diabetes.
Source: Stevanato Group